PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit.
NCT ID: NCT02673450
Last Updated: 2019-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2018-09-30
2020-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It also investigates a possible relationship between disturbance of the cyclic expression of melatonin and development of delirium in patients admitted to an intensive care unit.
Finally a possible relationship between genetic differences in the PER3 gene and development of delirium is investigated.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Delirium at the Intensive Care Unit - a Retrospective Cohort Study
NCT02603731
The Effect of Melatonin on Postoperative Delirium in Elderly ICU Patients
NCT02588742
Sleep and Circadian Rhythm Biomarkers of Postoperative Delirium
NCT06052397
Circadian Rhythm and Delirium in ICU
NCT05342987
Melatonin for Prevention of Post- Operative Delirium Pilot Study Protocol
NCT02903901
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cognitive deficiencies may affect large proportions of the post intensive care population and mild cognitive impairment was demonstrated for up to 40% of the patients when evaluated three months after discharge. Recovery was slow and at one year follow up, 25% of the patients still showed impairment comparable to mild traumatic brain injury.
The presence of delirium during ICU stay has been associated with a worsened cognitive outcome at both 3 and 12 months follow up. Both patient's global cognition and especially executive function was impaired. Furthermore, a longer duration of the delirium period was associated with a poorer cognitive function. Incidence of delirium has also shown association to higher mortality rates and a longer hospital stay when compared to patients without delirium. In previous studies, the second day of admission has had the highest incidence of delirium.
Alterations in sleep architecture with a more shallow sleep and disruptions of the sleep wake cycle, is common in both ICU patients and patients with delirium. Sleep deprivation is often seen in delirious patients, and consequently, it has been suggested to be a risk factor for development of delirium.
The circadian rhythm is an inborn cycle of biological activity based on 24 hour intervals, and the rhythmicity interacts with sleep homeostasis in order to regulate sleep-wake cycles of individuals. In humans, the circadian rhythm is controlled by the suprachiasmatic nucleus (SCN) (the circadian clock) mediating melatonin secretion from the pineal gland to regulate the sleep-wake cycle. A number of factors, especially daylight, influence the SCN.
When blue light (460-480 nm wavelengths) reaches the retina and excites photoreceptors, it communicates with the pineal gland and secretion of melatonin is reduced to a minimum. Melatonin is secreted at night when blue light is absent and promotes sleep by activation of melatonin receptors. Melatonin secretion also interacts with a number of body functions, including core body temperature and the cardiac and immune systems. It is one of the key molecules in circadian rhythmicity. The circadian rhythm is not only affected by light, but is also synchronized by other factors, including shift work, artificial light exposure and exercise.
A number of genetic markers known as clock genes play a major role in the circadian control of different processes in the body. These genes may determine an individual's chronotype (morningness/eveningness), sensitivity to sleep disturbance and sleep deprivation, but much of their significance and function is still unknown.
A group of genes named PERIOD genes are shown to be involved in determining individual sleep wake regulation. PERIOD3 (PER3) is found in three subtypes: PER3 4/4, PER3 4/5 and PER3 5/5. The numbers refer to a variable number of tandem repeat polymorphism where a motif of 54 nucleotides is repeated for 4 or 5 U. Studies in large populations have shown 10% of individuals to be homozygous for the 5'-variation, 50% for the 4'-variation and 40% to be heterozygous.
Patients with homozygosity of the long allele (PER35/5) have more slow wave sleep and longer sleep duration compared to the other sub-types. Though no difference in melatonin or cortisol levels where seen, the two types reacted very differently to sleep deprivation. PER35/5 individuals performed poorly on a variety of cognitive tests compared to PER34/4. This information might help to identify subgroups of patients especially sensitive to development of delirium.
A recent study explored the relationship between PER3 genotype and postoperative cognitive dysfunction and did not find an association. The distribution of PER3 subtypes were as expected from previous studies. However, a possible association between PER 3 genotypes and cognitive dysfunction has never been investigated in ICU patients.
A number of other genes are involved in the circadian rhythm. These genes are expressed in a rhythmic manner following the natural light/dark cycle.
In healthy subjects, severely disturbed expression of the clock genes Clock, Cry1-2, Per1-3, Rorα, Bmal1, Rev-erb and CSNK1ε has been demonstrated after injection of endotoxin.
In septic ICU patients, a desynchronised expression of Cry-1 and Per-2 has been demonstrated. This disturbance was linked to secretion of proinflammatory cytokines as tumor necrosis factor α (TNFα) and interleukin 6 (IL-6).
The implication of the above is that if a disturbed circadian rhythm can be demonstrated to be associated with patients in delirium, we might in the future be able to identify patients with a higher risk of developing delirium - even in comatose or heavily sedated patients. Something which is not possible with the current diagnostic methods.
In this study, we therefore wish to investigate the relationship between PER3 gene polymorphism and incidence of delirium. This may help to identify patient groups at a higher risk of developing delirium and potentially prevent or treat these patients at an earlier stage.
The other objective is to identify differences in melatonin and cyclic gene expression in delirious patients, compared to other critically ill patients. This may be a new perspective for the diagnosis of delirium in heavily sedated patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Melatonin (ATC N05CH01) or melatonin agonist (ATC N06AX) treatment prior to admission
* Known insomnia (daily hypnotic (ATC N05C) consumption or known sleep disorder)
* Patients discharged from the ICU during the test period (time from first to last blood sample)
* Patients who die during the test period
* Patients transferred to another hospital during ICU stay
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zealand University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stine Estrup
Ph.d. student MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ole Mathiesen, MD, PhD
Role: STUDY_CHAIR
Køge Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zealand University Hospital
Køge, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SE 2-16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.